Overview of Колме

Quick Facts

Property	Description
Active ingredient	Cyanamid (CyanaMide)
Form	Oral Solution (Drops)
Pharmacological class	Alcohol Deterrent Agent (Aldehyde Dehydrogenase Inhibitor)
Common use	Support for abstinence in chronic alcoholism
Origin	Synthetic Compound

Колме is a specialized medication classified as an alcohol deterrent agent utilized to support abstinence in individuals managing chronic alcohol dependence. The formulation is primarily recognized for its availability as a colorless, odorless liquid, which distinguishes its method of administration.

The Identity of Колме: An Alcohol Deterrent Agent

Колме is a prescription-only drug belonging to the pharmacological group of aldehyde dehydrogenase inhibitors, functioning specifically to deter alcohol use. This therapeutic class functions through its direct intervention in the metabolic pathway of ethanol. The medicine is supplied as an oral solution, typically administered in drops, which is the most common pharmaceutical form for agents containing Cyanamid. This specific classification means the drug's primary role is to establish a biochemical barrier that discourages drinking.

Composition and Origin: The Synthetic Substance Cyanamid

The core of the medicine’s function lies in its sole active ingredient, the substance Cyanamid (CyanaMide). Cyanamid is characterized as a synthetic compound, manufactured chemically, making Колме a single-ingredient product. Cyanamid is utilized as a medicine for the treatment of alcohol dependence, serving an established role in therapy. This active substance is suspended within an aqueous solution base, a composition feature that gives the medicine its neutral organoleptic properties, ensuring reliable delivery for aversion therapy.

General Purpose: What is the Core Benefit of Колме?

The essential purpose of Колме is to provide a decisive pharmacological support system for patients committed to maintaining long-term sobriety. The medicine achieves this by blocking the enzyme responsible for metabolizing the toxic alcohol intermediate, acetaldehyde, thereby rapidly creating a strong, conditioned aversion response upon drinking. This mechanism directly supports the patient's continuous goal of abstinence from alcohol.

What side effects are possible with Колме?

Possible Side Effects and Safety Information

The safety profile of Cyanamid (Колме) is characterized by documented adverse reactions and strict safety limitations, as classified by government regulatory agencies. The primary safety characteristic of this medication is its strong Reaction with Alcohol, which occurs upon consumption of ethanol while the drug is active in the body.

Officially documented adverse reactions are categorized by the systems they affect and their frequency:

Adverse Reactions Classified as Occasional

Adverse reactions classified as Occasional in regulatory documents involve several systems. These documented effects include fatigue and drowsiness (Nervous system/General), temporary changes in blood composition such as a transitory elevation of leukocytes (Blood and lymphatic system), and effects on the sensory and integumentary systems, such as tinnitus (Ear and labyrinth disorders) and skin rashes (Skin and subcutaneous tissue disorders).

Key Safety Constraints and Serious Concerns

The most significant safety constraint is the mandatory avoidance of all forms of alcohol to prevent the acute Reaction with Alcohol. The official label also documents a potential for anomalies in hepatic histology, a risk that has been associated with treatment periods superior to three months.

Safety restrictions for specific populations are also defined: the medication is formally contraindicated during pregnancy and lactation. Furthermore, it should not be used in individuals with pre-existing conditions such as severe hepatic or renal failure. The medicine also carries a constraint regarding simultaneous use with aldehydic drugs.

Overdose and Emergency Response

Overdose Scope and Manifestations

Overdose of the active substance, Cyanamid, is classified by regulatory authorities as carrying a high potential for severe harm, often categorized as Acute Toxicity Category I or 3 ("Toxic if swallowed"). The documented clinical presentation of severe overdose is characterized by profound CNS depression, which may include coma and somnolence.

Systemic and organ toxicity are critical concerns. Potential life-threatening outcomes documented in regulatory-aligned reports include hepatic necrosis (severe liver damage) and acute pancreatitis. Exposure through ingestion can also cause corrosive injury to the gastrointestinal tract, manifesting as esophagitis and gastritis. Systemic effects can include hypotension and tachycardia.

Emergency Actions and Required Care

Official Statements on Seeking Help:

Immediate medical attention and emergency services must be contacted immediately upon any suspicion of overdose due to the documented risk of severe organ damage and systemic collapse.
Treatment is strictly symptomatic and supportive, as no specific antidote is known for Cyanamid poisoning.
Continuous hospital monitoring is required to manage potential complications such as refractory shock and organ failure, adhering to standard protocols for detoxification.

The official regulatory profile strictly defines overdose as a life-threatening medical emergency primarily characterized by severe systemic failure and caustic tissue damage. This high level of acute toxicity and the absence of a specific reversal agent strictly mandate that medical help must be sought immediately for comprehensive, supportive management.

Therapeutic Uses of Колме

Primary Indication for Chronic Alcohol Dependence

Колме is generally utilized as a specialized pharmacological aid in the management of Chronic Alcohol Dependence and Alcohol Use Disorder (AUD). It is applicable in conditions characterized by periods of heightened symptoms involving frequent, compulsive alcohol consumption, including regular chronic dependence and frequent episodic abuse. The treatment is primarily designed for patients committed to discontinuing alcohol use, providing supportive pharmacological assistance to address the compulsive desire for alcohol, a symptom that interferes with daily functioning. Cyanamide serves as a component of the strategy to manage alcohol-seeking behaviors.

Support for Sustained Abstinence and Relapse Prevention

The medication's therapeutic domain centers on Relapse Prevention Strategy, specifically targeting the goal of maintaining abstinence after the initial cessation of drinking. It is considered relevant in contexts that involve comprehensive recovery plans. This approach helps address symptom groups like the anticipation of drinking in high-risk situations. The medication is applied in addressing the goal of lengthening the period of sustained abstinence and may help patients cope more steadily with symptom fluctuations, offering supportive relief during the recovery phase, and contributes to easing the overall symptom load.

The therapeutic use of this medicine is relevant in managing chronic alcoholism, supporting maintenance of sobriety, and assisting with relapse prevention. As a core benefit, the therapy supports general well-being during symptomatic phases.

Quick Fact: Relief for Compulsive Desire
Relevant Therapeutic Area	Chronic Alcohol Dependence / AUD
Symptom Focus	Compulsive desire for alcohol
Potential Benefit	May assist with the pursuit of sustained abstinence

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult patients managing Chronic Alcohol Dependence who are committed to abstinence (Patsnap Synapse 1.7).
Populations for whom use is not recommended	Children and adolescents (under 18 years), as safety and efficacy are not established for alcohol deterrence in this age group (Patsnap Synapse 1.2).
Pregnancy and Lactation	Use is contraindicated during both pregnancy and breastfeeding (Patsnap Synapse 1.7).

Contraindicated Populations and Conditions

Колме is contraindicated and must not be used in several specific populations, primarily due to the risk of exacerbating pre-existing conditions:

Hypersensitivity: Known allergy to Cyanamide or any product excipients.
Severe Organ Impairment: Patients with severe hepatic impairment (liver disease), severe renal impairment (kidney disease), severe cardiovascular disease, or severe respiratory disorders (Patsnap Synapse 1.7).

Use is also strictly restricted and requires cautionary monitoring in patients with less severe, pre-existing conditions, such as hypertension and mild-to-moderate hepatic impairment (Patsnap Synapse 1.2). The official eligibility profile is defined by these strict exclusion criteria, meaning only adults free of these severe comorbidities are deemed eligible.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Profile

The interaction profile for Колме (Cyanamid) is primarily defined by its severe, intended reaction with alcohol, as documented across international regulatory prescribing information. This information strictly details formal combination restrictions and resulting constraints.

Interaction Classification	Interacting Substance	Official Constraint
Formal Contraindication	Ethanol (Alcohol)	Strictly prohibited co-administration
Pharmacodynamic Interaction	Ethanol (Alcohol)	Leads to severe accumulation of the toxic metabolite acetaldehyde
Product Restriction	Alcohol-Containing Products	Avoidance of all forms (pharmaceuticals, foods, hygiene products)

Documented Interaction Statements

Co-administration with Alcohol/Ethanol is a formal contraindication due to the severe Cyanamide-Ethanol Reaction (CER). This reaction is officially described in regulatory texts as leading to marked physical symptoms, including severe facial flushing, tachycardia (rapid heart rate), and significant hypotension (drop in blood pressure). The constraint to avoid alcohol extends to all products that contain ethanol, including certain liquid pharmaceutical preparations, foods, and personal hygiene products. Regulatory summaries do not formally list specific interactions involving metabolic enzymes (such as Cytochrome P450) or drug transporters with other co-administered medicinal products, making the interaction with alcohol the sole determinant of the official interaction structure.

Mechanism of Action

The mechanism of action for Колме (Cyanamide) is a targeted, peripheral intervention in the body's method of breaking down alcohol, relying exclusively on enzymatic blockade to produce its characteristic physiological effect.

Irreversible Aldehyde Dehydrogenase Inhibition

The drug's primary biological action involves the irreversible inhibition of the Aldehyde Dehydrogenase ( ALDH) enzyme, specifically the mitochondrial ALDH2 isozyme found primarily in the liver. This covalent binding neutralizes the enzyme's function until the body can synthesize new molecules, thus establishing a persistent metabolic block tied to enzyme turnover rather than drug elimination kinetics.

Pathological Acetaldehyde Accumulation Cascade

By blocking ALDH, Cyanamide halts the conversion of the highly toxic intermediate, acetaldehyde, into acetate, forcing its rapid and pathological accumulation in the bloodstream upon alcohol consumption . This systemic buildup is the core mechanism that initiates the drug's characteristic physiological consequences.

Systemic Vasoactive Mediator Release

The high concentration of acetaldehyde acts as a chemical trigger, leading to the rapid release of vasoactive mediators (such as histamine) and the stimulation of the Autonomic Nervous System. This cascade produces significant peripheral vasodilation (flushing) and reflex tachycardia, connecting the molecular failure of detoxification directly to significant systemic physiological changes.

Dosage and Administration Information

Administration and Usage

Колме (Cyanamid) is administered via the oral route as a liquid solution, consistent with its formulation as drops.

Standard Dosing and Frequency

The standard adult dose for pharmacological support of abstinence ranges from 50 to 200 mg of the active ingredient per day. This dosage is typically administered in one or two divided doses daily.

Administration Context and Regimen

To facilitate consistent intake, the solution may be mixed into non-alcoholic food or beverages before consumption. The medicine must never be co-administered with any substance containing alcohol, including certain medicines, cosmetics, or food items, as this constitutes a core administration constraint.

The treatment regimen is structured for continuous, sustained use. The initial dosage is provisional and is subject to adjustment after one week of treatment following professional assessment to determine the appropriate maintenance dose.

Missed Dose Instructions

If a dose is missed, it is typically taken as soon as the patient remembers. If the time for the next scheduled dose is near, the missed dose is skipped. Taking a double dose to compensate is strictly forbidden.

Administration Scope	Detail
Route of administration	Oral (liquid solution)
Dosing schedule	50 to 200 mg per day
Frequency pattern	Daily (1 to 2 divided doses)

Recent Clinical Evidence

Research evidence / Overview of Studies for Колме (Cyanamide)

1. Evidence for Use in Chronic Alcohol Dependence and Abstinence Support

Cyanamide was studied for its use as a prescribed support for individuals managing chronic alcohol dependence who are actively committed to sobriety. Research has explored how the medicine was observed in studies examining patient outcomes when used as a deterrent within comprehensive treatment programs. The primary evidence comes from Randomized Controlled Trials (RCTs) and comparative studies where cyanamide was evaluated against alternate agents.

Studies monitored several key measures of progress, including the total duration of continuous abstinence and the time elapsed until the first relapse. These short-term trials were used in research exploring how symptoms change over time regarding the compulsion to drink and maintaining sobriety immediately following detoxification.

Research highlights measured patterns where a longer total duration of abstinence was observed in groups receiving cyanamide compared to those receiving placebo. These results largely reflect outcomes in specific groups: patients who are highly motivated and receiving the medication under supervised administration. This research contributes to the broader evidence landscape by exploring its role within treatment protocols designed to support abstinence.

2. Research Landscape and Comparator Studies

The overall structure of the evidence base includes systematic reviews and meta-analyses, which involve pooling data from multiple primary studies to summarize patterns documented across multiple primary studies. Research explored how cyanamide's measured outcomes compared to both an inactive control and to an alternate agent studied in the management of alcohol dependence.

3. Long-Term Studies and Follow-Up Data

The research currently available primarily focuses on short-term study periods. The longest duration of the most definitive controlled trials, the RCTs, typically featured a follow-up of around 90 days (three months) of active treatment. Consequently, information on long-term effects are not fully established. While observational studies were observed in some clinical settings for longer periods, the controlled data for outcomes like sustained abstinence beyond several months is limited.

4. Evidence in Special Populations

Most clinical evidence for cyanamide was evaluated in the main group of adult patients with alcohol dependence. However, specific studies have been studied for their applicability in certain specialized groups, such as adolescents aged 16–19 years. Because the sample sizes in these particular studies were modest, the findings indicate patterns observed only within that small, specific group. Data for certain groups, such as older adults or individuals with multiple concurrent health issues, remain insufficient and are still emerging.

5. What is Still Uncertain About Колме Research

A noted research limitation is that follow-up durations were limited in key controlled trials, meaning there is limited information for long-term outcomes and the durability of measured effects. Additionally, the outcomes reported in trials often rely heavily on supervised administration and high patient commitment. Therefore, the applicability of these findings to unsupervised, real-world settings is uncertain, and means the results apply only to the specific conditions under which they were conducted.

Key Studies & References

Comparison of Cyanamide and Disulfiram in Effects on Liver Function (2000)

Frequently Asked Questions (FAQ)

Common questions about Колме (FAQ)

Q: What are the most common side effects people report with Колме?

Official documents describe a range of occasional adverse reactions related to the medicine. These include effects such as fatigue, drowsiness, skin rash, and tinnitus (ringing in the ears). Regulatory lists classify these effects based on their reported frequency in clinical use.

Q: Are there any major diet restrictions while taking Колме?

The primary official constraint is the strict avoidance of all products and foods that contain alcohol (ethanol). Regulatory documents do not formally list any major restrictions on specific non-alcoholic food items, such as particular fruits or vitamins.

Q: What kind of research has been done on the long-term effects of Колме?

Studies and official information indicate that the longest controlled clinical trials typically followed patients for approximately 90 days (three months) of active treatment. Because of this, evidence for long-term outcomes and effects beyond that period is considered limited.

Q: What is the difference between addiction and dependence in the context of Колме?

The medicine is officially described as supporting abstinence in the management of chronic alcohol dependence. While people use both terms, formal regulatory texts consistently use the specific medical term dependence to describe the condition the medication is studied for.

Q: Is Колме a type of addiction treatment?

The medication is officially classified as an alcohol deterrent agent used to support individuals managing chronic alcohol dependence and maintaining abstinence.

Q: How long does the effect of Колме last after stopping?

The medication works through the irreversible inhibition of an enzyme. The physiological effect lasts until the body naturally produces new enzyme molecules to replace the blocked ones. This process is tied to the drug’s irreversible mechanism and takes a period of time after the medication is stopped.

Q: Does Колме interact with common pain relievers like ibuprofen?

Official regulatory summaries do not formally list specific drug-drug interactions with common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs), or other co-administered medicinal products. The key restriction is centered exclusively on alcohol (ethanol).

Q: Does taking Колме affect driving ability?

Official adverse reaction documents list occasional side effects such as fatigue and drowsiness. These factors are noted as potentially affecting the ability to drive or safely operate machinery.

Q: Is it necessary to use Колме for a long period of time?

Official product information states that the treatment regimen is structured for continuous, sustained use. The initial dosage is subject to professional adjustment after one week.

Q: Is it possible to develop an allergy to Колме?

The official contraindications for the medication include having a known hypersensitivity (or allergy) to Cyanamide, the active ingredient, or any of the product's excipients. This indicates that allergic potential is officially acknowledged.

Q: Are there any restrictions on non-alcoholic beer while using Колме?

Official documentation mandates the strict avoidance of all products that contain alcohol/ethanol. This core constraint extends to certain beverages, foods, and hygiene products that may contain trace amounts of alcohol.

Q: Does Колме interact with prescription drugs for depression or anxiety?

Official regulatory summaries do not formally list specific interactions with common prescription drugs used for depression or anxiety. The central restriction detailed in the regulatory texts is exclusively related to alcohol (ethanol).

Q: Can Колме be used alongside behavioral therapy?

Studies have examined the medicine’s effects when it is used as a pharmacological deterrent within comprehensive treatment programs, confirming its role in a broader treatment strategy.

Q: Why is Колме sometimes referred to by a different chemical name?

The active substance in the medicine, Cyanamid, is a chemical compound. Because of this, it is also referred to in technical and scientific literature by its official chemical names, such as Hydrogen Cyanamide or CyanaMide.

Q: Do doctors in other countries use Колме for the same purpose?

Regulatory bodies, such as the World Health Organization (WHO), have recognized the active substance, Cyanamide, as an essential medicine for the treatment of alcohol dependence. This confirms its established international role in therapy.

Q: Are the effects of Колме reversible if use is stopped?

The medication's effect is based on the irreversible inhibition of an enzyme. While the drug itself is eliminated, the return of normal metabolic function depends entirely on the body synthesizing new enzyme molecules, which occurs over time after the medicine is stopped.

Q: Does Колме affect sleep patterns?

Official documentation lists drowsiness and fatigue among the occasional adverse reactions reported. These central nervous system effects are factors that could potentially impact a patient's normal sleep-wake cycle.

Q: Is Колме used for treating any other conditions besides alcohol dependence?

Official regulatory documents list the approved use of the medicine solely as support for abstinence in individuals managing chronic alcohol dependence.

Q: Do children or adolescents use Колме?

Official regulatory documents state that the safety and efficacy of the medication are not established for use in children and adolescents (those under 18 years) for alcohol deterrence.

Q: What is the half-life of the active ingredient in Колме?

Technical pharmacokinetic sources describe the active ingredient's profile. It is noted as having an approximate biological half-life of 92 minutes.

How should Колме be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documentation requires strict control over the storage and disposal of this product, primarily due to the chemical sensitivity and environmental classification of the active substance.

Storage Category	Official Requirements
Temperature & Moisture	Store in a refrigerated environment, typically 2 C to 8 C. The container must be kept tightly closed and protected from moisture and excess heat.
Handling & Packaging	Store in a well-ventilated and locked area to prevent unauthorized access. Avoid contact with acids, bases, and strong oxidizing agents.
In-Use Stability	The prepared solution is generally stable for at least 3 months if stored at or below 20 C, though stricter refrigeration is required for long-term storage.
Disposal	Disposal of the contents and container must occur via an approved waste disposal plant, such as licensed chemical destruction or incineration. Do not flush the product into drains or release it into the environment, as it is classified as harmful to aquatic life.

These measures are mandatory to maintain chemical stability and ensure environmental protection as dictated by governmental safety and waste regulations.

Колме